본문으로 건너뛰기
← 뒤로

Single-cell spatial atlas of high-grade serous ovarian cancer uncovers MHC class II as a key predictor of spatial tumor ecosystems and clinical outcomes.

Cancer discovery 2026

Perez-Villatoro F, Shabanova A, van Wagensveld L, Junquera A, Niemiec I, Hincapié-Otero MM, Kang Z, Falco MM, Birgin K, Wolf S, Anttila E, Anandagoda G, Casado J, Marcus E, Gaillard D, Kahelin E, Chamchougia F, Salko M, Shah S, Russo S, Chiaro J, Grönholm M, Ndika J, Kari OK, iCAN I, Sonke GS, Van de Vijver KK, Fpm Kruitwagen R, van der Aa M, Virtanen A, Cerullo V, Vähärautio A, Sorger PK, Horlings HM, Farkkila A

📝 환자 설명용 한 줄

The tumor microenvironment in high-grade serous ovarian carcinoma (HGSC) is a complex network of malignant-host cell interactions, yet its orchestration remains poorly understood.

이 논문을 인용하기

BibTeX ↓ RIS ↓
APA Perez-Villatoro F, Shabanova A, et al. (2026). Single-cell spatial atlas of high-grade serous ovarian cancer uncovers MHC class II as a key predictor of spatial tumor ecosystems and clinical outcomes.. Cancer discovery. https://doi.org/10.1158/2159-8290.CD-25-1492
MLA Perez-Villatoro F, et al.. "Single-cell spatial atlas of high-grade serous ovarian cancer uncovers MHC class II as a key predictor of spatial tumor ecosystems and clinical outcomes.." Cancer discovery, 2026.
PMID 41661089

Abstract

The tumor microenvironment in high-grade serous ovarian carcinoma (HGSC) is a complex network of malignant-host cell interactions, yet its orchestration remains poorly understood. We present a single-cell spatial atlas of metastatic HGSC from 280 patients, integrating high-dimensional imaging and molecular profiling. Analyzing 929 single-cell maps, we identify spatial domains with diverse cell compositions and show that immune cell co-infiltration at the tumor-stroma interface impacts clinical outcomes. Using CEFIIRA, we find that tumor cell MHCII expression is a key predictor of prolonged survival. Validation with deconvoluted, single-cell, and two distinct spatial transcriptomic datasets, along with immunopeptidomic analysis, confirms that MHCII expression correlates with immune activation, antigen presentation, and TCR clonality. Using a patient-derived immuno-oncology platform, we demonstrate that tumor MHCII expression associates with increased CD8+ T cell cytotoxicity after PD-1 blockade, while blocking MHCII inhibits this activation. Our atlas offers new insights into immune activation, potentially improving patient stratification in HGSC.